A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC Injection in Adult Participants With Moderate to Severe Atopic Dermatitis
Latest Information Update: 16 Jun 2025
At a glance
- Drugs GSK 1070806 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms AtDventure
- Sponsors GSK
Most Recent Events
- 10 Jun 2025 Planned End Date changed from 12 Jan 2026 to 24 Jul 2025.
- 10 Jun 2025 Planned primary completion date changed from 20 Oct 2025 to 24 Jul 2025.
- 06 May 2025 Status changed from recruiting to active, no longer recruiting.